Google
CALC 株価分析 — Calcimedica, Inc. Common Stock (Healthcare >> Biotechnology)
CALC に関するよくある質問
CALCのPER（株価収益率）は？
Calcimedica, Inc. Common Stock（CALC）は現在PER 3.17倍で取引されています。
CALCのROE（自己資本利益率）は？
Calcimedica, Inc. Common StockのROEは1,770.29%です。
CALCの配当利回りは？
Calcimedica, Inc. Common Stockの配当利回りは0.00%です。
CALCの品質スコア（Quality Score）は？
当社のAIはCALCの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CALCは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CALCはどのセクターに属しますか？
Calcimedica, Inc. Common StockはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
CALC AI Analysis Summary
Our AI summary for CALC: Calcimedica, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.17, ROE of 1,770.29%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.75
Price
-0.25
(-24.73%)
Day Change
|
|
|---|
CALC, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.75 |
| PBV / Sector |
-14.31 / 44,219.29
|
| Earning Per Share | -0.93 |
| PE / Sector |
3.17 / 19.28
GREAT
|
| PEG or PE/Growth / Sector |
-0.07 / 1.23
|
| Average 1M Daily Value |
0.27 M
GREAT
|
| Average 1W Daily Value |
0.39 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:17 |
| Symbol | CALC |
| Name | CALCIMEDICA, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 15.80 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 15.80 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 505 Coast Boulevard South, La Jolla, CA, United States, 92037
Phone: 858 952 5500
Website: https://calcimedica.com
Sector: Healthcare >> Biotechnology
Description: CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
